Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.

Clinical and translational science - 1 Jun 2022

Hammer Christian, Ruppel Jane, Kamen Lynn, Hunkapiller Julie, Mellman Ira, Quarmby Valerie

Abstract excerpt

The treatment of diseases with biologic agents can result in the formation of antidrug antibodies (ADA). Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown to be associated with occurrence of ADA for several biologics. Here, we performed an HLA-wide association study in 1982 patients treated with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to HLA-DRB1 Chains

Share to Immune Cell Function and Interaction

Share to Immunotherapy and Immune Responses

Share to Monoclonal and Polyclonal Antibodies Research

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35263013
DOI: 10.1111/cts.13264
PMCID: PMC9199883

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.PMID 35263013Read ↗

Allelic Variation in<i>HLA-DRB1</i>is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing<i>in Vitro</i>Semantic proximity Read ↗

HLA Class II Alleles are associated with Anti-Drug Antibodies in Ulcerative Colitis Patients Treated with EtrolizumabSemantic proximity Read ↗

HLA Class II Alleles Are Associated With Anti-Drug Antibodies in Ulcerative Colitis Patients Treated With Etrolizumab.Semantic proximity Read ↗

Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity Read ↗

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable PatientsSemantic proximity Read ↗

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.Semantic proximity Read ↗

Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy <i>in vivo</i>Semantic proximity Read ↗

Association between germ-line HLA and immune-related adverse eventsSemantic proximity Read ↗

Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.Semantic proximity Read ↗

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.